June 09, 2022 09:05 ET | Source: Clarus Therapeutics Holdings, Inc. Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions
NORTHBROOK, Ill., June 09, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that new data for JATENZO (testosterone undecanoate) will be presented in the form of an abstract at ENDO 2022, the Endocrine Society’s annual meeting, taking place at the Georgia World Congress Center in Atlanta June 11-14, 2022.
Details on the abstract presentation for JATENZO are below.
Abstract Title: Comparison Between Single Time Point Testing and 24-Hour Average Concentration of Total Testosterone in Hypogonadal Men Treated with an Oral Testosterone Undecanoate Softgel (JATENZO®) Date/time: Monday, June 13, 2022, 12:30 p.m. – 2:30 p.m. ET Session/location: PMON267, Hall A1
About Male Hypogonadism Male hypogonadism is a condition that results when the testes do not produce enough testosterone. Symptoms associated with male hypogonadism can include depression, decreased sex drive, decreased muscle mass, and decreased bone density, among others. An estimated 20 million men in the United States have hypogonadism, with approximately six million patients diagnosed. Treatments for male hypogonadism may include testosterone replacement therapy.
About Clarus Therapeutics Holdings, Inc. Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women – including potential therapies for orphan indications. Clarus’ first commercial product is JATENZO® (testosterone undecanoate). For more information, visit www.clarustherapeutics.com and www.jatenzo.com. Follow us on Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics).
JATENZO® is a registered trademark of Clarus Therapeutics Holdings, Inc.
Clarus Contact: Kara Stancell Vice President, Investor Relations & Corporate Communications kstancell@clarustherapeutics.com (847) 562-4300 x 206
Indication JATENZO® (testosterone undecanoate) capsules, CIII, is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:
Limitation of use Safety and efficacy of JATENZO in males less than 18 years old have not been established.
WARNING: INCREASES IN BLOOD PRESSURE
CONTRAINDICATIONS JATENZO is contraindicated in men with breast cancer or known or suspected prostate cancer. JATENZO is contraindicated in women who are pregnant as testosterone may cause fetal harm.
ADVERSE EVENTS The most common adverse events of JATENZO (incidence ≥2%) are headache (5%), increased hematocrit (5%), hypertension (4%), decreased HDL (3%), and nausea (2%).
These are not all of the risks associated with JATENZO. For more information, click here for full Prescribing Information, including BOXED WARNING on increases in blood pressure. You can also obtain information regarding JATENZO at www.jatenzo.com.
© 2022 Clarus Therapeutics, Inc. All rights reserved.